Non-Cochrane · other · PM42886444
SOX10 Expression in Primary Salivary Gland Tumors: A Meta-Analysis.
Tahvanainen Otto, Lagerstam Henri, Kalfert David, et al. · Head and neck pathology · 2026 · PubMed · doi:10.1007/s12105-026-01975-3
Findings
22 findings
| Population | ||||
|---|---|---|---|---|
| Primary salivary gland tumors: Pleomorphic adenoma | SOX10 immunohistochemistry | None (single-group pooled proportion) | SOX10 immunohistochemical positivity (proportion of tumors SOX10 positive) Pathology laboratories; histological (and some cytological) tumor samples | Proportion (%) 95.8 [91.7, 99.9] GRADE not reported 7 studies · 174 participants |
| Primary salivary gland tumors: Basal cell adenoma | SOX10 immunohistochemistry | None (single-group pooled proportion) | SOX10 immunohistochemical positivity (proportion of tumors SOX10 positive) Pathology laboratories; histological (and some cytological) tumor samples | Proportion (%) 91.3 [80.2, 102.5] GRADE not reported 4 studies · 21 participants |
| Primary salivary gland tumors: Basal cell adenocarcinoma | SOX10 immunohistochemistry | None (single-group pooled proportion) | SOX10 immunohistochemical positivity (proportion of tumors SOX10 positive) Pathology laboratories; histological (and some cytological) tumor samples | Proportion (%) 84.8 [67.3, 102.3] GRADE not reported 2 studies · 15 participants |
| Primary salivary gland tumors: Adenoid cystic carcinoma | SOX10 immunohistochemistry | None (single-group pooled proportion) | SOX10 immunohistochemical positivity (proportion of tumors SOX10 positive) Pathology laboratories; histological (and some cytological) tumor samples | Proportion (%) 96.6 [94.1, 99.2] GRADE not reported 9 studies · 181 participants |
| Primary salivary gland tumors: Myoepithelioma | SOX10 immunohistochemistry | None (single-group pooled proportion) | SOX10 immunohistochemical positivity (proportion of tumors SOX10 positive) Pathology laboratories; histological (and some cytological) tumor samples | Proportion (%) 75.2 [52.0, 98.4] GRADE not reported 3 studies · 14 participants |
| Primary salivary gland Myoepithelial carcinoma | SOX10 immunohistochemistry | None | SOX10 positivity | Pooled proportion (%) 75.0 [15.0, 100.0] GRADE not reported 2 studies |
| Primary salivary gland tumors: Epithelial-myoepithelial carcinoma | SOX10 immunohistochemistry | None (single-group pooled proportion) | SOX10 immunohistochemical positivity (proportion of tumors SOX10 positive) Pathology laboratories; histological (and some cytological) tumor samples | Proportion (%) 89.0 [71.6, 106.5] GRADE not reported 3 studies · 9 participants |
| Primary salivary gland tumors: Polymorphous adenocarcinoma | SOX10 immunohistochemistry | None (single-group pooled proportion) | SOX10 immunohistochemical positivity (proportion of tumors SOX10 positive) Pathology laboratories; histological (and some cytological) tumor samples | Proportion (%) 97.4 [92.3, 102.6] GRADE not reported 3 studies · 33 participants |
| Primary salivary gland Warthin tumor (WT) | SOX10 immunohistochemistry | None | SOX10 positivity | Pooled proportion (%) 2.3 [0, 7.0] GRADE not reported 3 studies |
| Primary salivary gland Oncocytoma | SOX10 immunohistochemistry | None | SOX10 positivity | Pooled proportion (%) 8.0 [-2.7, 18.7] GRADE not reported 5 studies |
| Primary salivary gland tumors: Acinic cell carcinoma | SOX10 immunohistochemistry | None (single-group pooled proportion) | SOX10 immunohistochemical positivity (proportion of tumors SOX10 positive) Pathology laboratories; histological (and some cytological) tumor samples | Proportion (%) 97.4 [94.1, 100.6] GRADE not reported 7 studies · 95 participants |
| Primary salivary gland Secretory carcinoma (SC) | SOX10 immunohistochemistry | None | SOX10 positivity | Pooled proportion (%) 79.9 [55.1, 104.7] GRADE not reported 9 studies |
| Primary salivary gland Mucoepidermoid carcinoma (MEC) | SOX10 immunohistochemistry | None | SOX10 positivity | Pooled proportion (%) 20.2 [2.8, 37.6] GRADE not reported 9 studies |
| Primary salivary gland Salivary duct carcinoma (SDC) | SOX10 immunohistochemistry | None | SOX10 positivity | Pooled proportion (%) 3.7 [-0.6, 8.1] GRADE not reported 8 studies |
| Primary salivary gland Hyalinizing clear cell carcinoma (HCCC) | SOX10 immunohistochemistry | None | SOX10 positivity | Pooled proportion (%) 8.8 [-1.9, 19.6] GRADE not reported 3 studies |
| Primary salivary gland Adenocarcinoma, NOS | SOX10 immunohistochemistry | None | SOX10 positivity | Pooled proportion (%) 39.8 [-4.3, 84.0] GRADE not reported 4 studies |
| Primary salivary gland tumors: Canalicular adenoma | SOX10 immunohistochemistry | None (single-group pooled proportion) | SOX10 immunohistochemical positivity (proportion of tumors SOX10 positive) Pathology laboratories; histological (and some cytological) tumor samples | Proportion (%) 98.9 [96.4, 101.4] GRADE not reported 2 studies · 62 participants |
| Primary salivary gland tumors: Intraductal carcinoma (all subtypes combined) | SOX10 immunohistochemistry | None (single-group pooled proportion) | SOX10 immunohistochemical positivity (proportion of tumors SOX10 positive) Pathology laboratories; histological (and some cytological) tumor samples | Proportion (%) 56.4 [17.6, 95.1] GRADE not reported 5 studies · 29 participants |
| Primary salivary gland Intraductal carcinoma– intercalated type | SOX10 immunohistochemistry | None | SOX10 positivity | Pooled proportion (%) 90.8 [75.9, 105.8] GRADE not reported 3 studies |
| Primary salivary gland Intraductal carcinoma– apocrine type | SOX10 immunohistochemistry | None | SOX10 positivity | Pooled proportion (%) 10.3 [-10.4, 31.1] GRADE not reported 2 studies |
| Primary salivary gland Microsecretory carcinoma | SOX10 immunohistochemistry | None | SOX10 positivity | Pooled proportion (%) 96.1 [87.2, 105.0] GRADE not reported 2 studies |
| Primary salivary gland Sialadenoma papilliferum (SP) (all subtypes) | SOX10 immunohistochemistry | None | SOX10 positivity | Pooled proportion (%) 50.0 [0, 100] GRADE not reported 2 studies |
Included primary studies 35
Open in Studies| Study | Year | Also included by | Outcomes it informs here | Trial data |
|---|---|---|---|---|
| Adkins BD 2020 SOX10 and GATA3 in Adenoid Cystic Carcinoma and Polymorphous Adenocarcinoma. PMID:31222589 | 2020 | this review only | not stated | not extracted yet |
| Agaimy A 2021 ALK Rearrangements Characterize 2 Distinct Types of Salivary Gland Carcinomas: Clinicopathologic and Molecular Analysis of 4 Cases and… PMID:33871952 | 2021 | this review only | not stated | not extracted yet |
| Agaimy A 2022 HMGA2-WIF1 Rearrangements Characterize a Distinctive Subset of Salivary Pleomorphic Adenomas With Prominent Trabecular (Canalicular… PMID:34324456 | 2022 | this review only | not stated | not extracted yet |
| Baghai F 2017 Clinicopathologic and molecular characterization of mammary analogue secretory carcinoma of salivary gland origin. PMID:28781197 | 2017 | this review only | not stated | not extracted yet |
| Bishop JA 2021 Microsecretory Adenocarcinoma of Salivary Glands: An Expanded Series of 24 Cases. PMID:33982215 | 2021 | this review only | not stated | not extracted yet |
| Bundele M 2021 Mucoacinar Carcinoma: A Rare Variant of Mucoepidermoid Carcinoma. PMID:34091485 | 2021 | this review only | not stated | not extracted yet |
| Dababneh MN 2024 HMGA2-positive salivary gland neoplasms with prominent trabecular/canalicular morphology: a focus on carcinomas arising within this… PMID:39360582 | 2025 | this review only | not stated | not extracted yet |
| de Aquino SN 2025 Clinicopathological and immunohistochemical aspects of conventional and unicystic canalicular adenoma: a case series. PMID:39306518 | 2025 | this review only | not stated | not extracted yet |
| Delfin L 2024 Pure Apocrine Intraductal Carcinoma of Salivary Glands: Reassessment of Molecular Underpinnings and Behavior. PMID:38935197 | 2024 | this review only | not stated | not extracted yet |
| Fisch AS 2021 Intraductal carcinoma of the salivary gland with NCOA4-RET: expanding the morphologic spectrum and an algorithmic diagnostic approach. PMID:33991527 | 2021 | this review only | not stated | not extracted yet |
| Hsieh MS 2016 SOX10-positive salivary gland tumors: a growing list, including mammary analogue secretory carcinoma of the salivary gland, sialoblastoma,… PMID:27327192 | 2016 | this review only | not stated | not extracted yet |
| Hsieh MS 2020 Salivary Sialadenoma Papilliferum Consists of Two Morphologically, Immunophenotypically, and Genetically Distinct Subtypes. PMID:31473937 | 2020 | this review only | not stated | not extracted yet |
| Hsieh MS 2020 Clinicopathological study of intraductal carcinoma of the salivary gland, with emphasis on the apocrine type. PMID:32383006 | 2020 | this review only | not stated | not extracted yet |
| Klubíčková N 2025 Expanding the Molecular-genetic Spectrum of Canalicular Adenoma-like Subtype of Pleomorphic Adenoma of Salivary Glands. PMID:40033554 | 2025 | this review only | not stated | not extracted yet |
| Ko YCK 2020 Gene Expression Profiling of Head and Neck Tumors Identifies FOXP1 and SOX10 Expression as Useful for Distinguishing Ameloblastoma From… PMID:31895100 | 2020 | this review only | not stated | not extracted yet |
| Kobayashi K 2024 An Institutional Experience of Core Needle Biopsy with Cooperative Implementation by Pathologists and Head and Neck Oncologists in… PMID:39560855 | 2024 | this review only | not stated | not extracted yet |
| Krings G 2017 Genomic profiling of breast secretory carcinomas reveals distinct genetics from other breast cancers and similarity to mammary analog… PMID:28548128 | 2017 | this review only | not stated | not extracted yet |
| Lee JH 2018 PLAG1, SOX10, and Myb Expression in Benign and Malignant Salivary Gland Neoplasms. PMID:30424592 | 2019 | this review only | not stated | not extracted yet |
| Luna-Ortiz K 2021 Clinicopathological and immunohistochemical behavior of ductal carcinoma of the salivary and lacrimal gland in a Mexican Mestizo population. PMID:33763743 | 2022 | this review only | not stated | not extracted yet |
| Mahomed F 2024 ETV6 Molecular Heterogeneity in Salivary Secretory Carcinoma: A Case Series Report and Literature Review. PMID:39101978 | 2024 | this review only | not stated | not extracted yet |
| McLean-Holden AC 2022 Frankly Invasive Carcinoma Ex-intraductal Carcinoma: Expanding on an Emerging and Perplexing Concept in Salivary Gland Tumor Pathology. PMID:34985683 | 2022 | this review only | not stated | not extracted yet |
| Ni H 2016 Extended immunologic and genetic lineage of mammary analogue secretory carcinoma of salivary glands. PMID:27658560 | 2016 | this review only | not stated | not extracted yet |
| North JP 2015 Detection of MYB Alterations and Other Immunohistochemical Markers in Primary Cutaneous Adenoid Cystic Carcinoma. PMID:26076064 | 2015 | this review only | not stated | not extracted yet |
| Ohtomo R 2013 SOX10 is a novel marker of acinus and intercalated duct differentiation in salivary gland tumors: a clue to the histogenesis for tumor… PMID:23558573 | 2013 | this review only | not stated | not extracted yet |
| Owosho AA 2023 Clinicopathologic Study of Sialadenoma Papilliferum of the Minor Salivary Glands: A Series of 8 New Cases With BRAF V600E… PMID:36632022 | 2023 | this review only | not stated | not extracted yet |
| Rooper LM 2023 Recurrent IDH2 Mutations in Salivary Gland Striated Duct Adenoma Define an Expanded Histologic Spectrum Distinct From Canalicular Adenoma. PMID:36510691 | 2023 | this review only | not stated | not extracted yet |
| Sakyo A 2025 NKX3.1 Helps Distinguish Hyalinizing Clear Cell Carcinoma From Other Clear Cell Salivary Gland Neoplasms. PMID:39617100 | 2025 | this review only | not stated | not extracted yet |
| Schmitt AC 2015 Expression of SOX10 in Salivary Gland Oncocytic Neoplasms: A Review and a Comparative Analysis with Other Immunohistochemical Markers. PMID:26619208 | 2015 | this review only | not stated | not extracted yet |
| Skálová A 2020 Molecular Profiling of Salivary Oncocytic Mucoepidermoid Carcinomas Helps to Resolve Differential Diagnostic Dilemma With Low-grade… PMID:33002921 | 2020 | this review only | not stated | not extracted yet |
| Skálová A 2022 Sclerosing Polycystic Adenoma of Salivary Glands: A Novel Neoplasm Characterized by PI3K-AKT Pathway Alterations-New Insights Into a… PMID:34510113 | 2022 | this review only | not stated | not extracted yet |
| Takamatsu M 2018 Hyalinizing clear cell carcinoma of the bronchial glands: presentation of three cases and pathological comparisons with salivary gland… PMID:29434341 | 2018 | this review only | not stated | not extracted yet |
| Thompson LDR 2015 Canalicular adenoma: a clinicopathologic and immunohistochemical analysis of 67 cases with a review of the literature. PMID:25141970 | 2015 | this review only | not stated | not extracted yet |
| Urano M 2015 Characterization of mammary analogue secretory carcinoma of the salivary gland: discrimination from its mimics by the presence of the… PMID:25456394 | 2015 | this review only | not stated | not extracted yet |
| Weinreb I 2023 Microcribriform Adenocarcinoma of Salivary Glands: A Unique Tumor Entity Characterized by an SS18::ZBTB7A Fusion. PMID:36221318 | 2023 | this review only | not stated | not extracted yet |
| Yang C 2019 SOX10 Is a Sensitive Marker for Breast and Salivary Gland Adenoid Cystic Carcinoma: Immunohistochemical Characterization of Adenoid Cystic… PMID:31105427 | 2019 | this review only | not stated | not extracted yet |
Review question
| Element | Planned (methods) | Found (results) |
|---|---|---|
| Population | Primary salivary gland tumors (histological and cytological samples) | 1146 histological and 35 cytological primary salivary gland tumor samples, 32 histological entities (n=35 studies) |
| Intervention | SOX10 immunohistochemistry | SOX10 immunohistochemistry with various antibodies and clones (polyclonal, EP268, SP267, N-20, A-2, BC34) |
| Comparison | Not specified | Not specified |
| Outcomes | Proportion of SOX10-positive tumors per tumor entity; staining pattern, cell type, intensity, percentage of positive cells; antibody source, clone and dilution | Pooled SOX10 positivity for 22 entity analyses (20 entities eligible, plus intraductal carcinoma subtypes); other entities and cytology summarized descriptively |
| Study designs | Original studies of SOX10 immunohistochemistry in primary salivary gland tumors (reviews, meta-analyses, case reports and non-English studies excluded) | Original immunohistochemical studies (n=35), published 2013 to 2025 |
| Timing | Not specified | Not specified |